Oberland Capital
Venture debtNew York · Growth–Late Stage · 20 people tracked
Also known as OBERLAND CAPITAL MANAGEMENT LLC
Investment thesis
Oberland Capital is a dedicated healthcare investor that specializes in customized, flexible investment structures for clinical-stage and commercial-stage companies. It applies a fundamental, research-driven approach combined with quantitative methods to back innovative technologies aimed at improving patient outcomes worldwide. The firm focuses on the pharmaceutical, biotechnology, medical device, and diagnostic sectors, collaborating with management teams to create tailored financing that helps them access significant capital for accelerating R&D, expanding commercial infrastructure, acquiring assets or companies, and refinancing existing capital sources. Its partners span public and private companies, research institutions, and individual inventors, and it executes structured investments globally.
Source: firm website, verified Jul 31, 2026.
Team · 20 people
from the firm's websiteManaging Partner who previously co-managed Paul Capital's healthcare royalty platform and was CEO of Microban International. Earned a J.D. and M.B.A. from NYU and a B.A. from the University of Pennsylvania.
Managing Partner who previously co-managed Paul Capital's healthcare royalty platform and spent nearly a decade at Johnson & Johnson, including principal investing at J&J Development Corporation. Holds a Masters from Yale School of Management and an engineering diploma from the Swiss Federal Institute of Technology.
Partner who previously held Managing Director roles at Vatera Healthcare Partners, Essex Woodlands, and Warburg Pincus, and began her career at Goldman Sachs. Earned an M.B.A. and A.B. from Harvard.
Partner who was previously an investment professional at Paul Capital and a healthcare consultant at the Frankel Group. Holds an M.B.A. from Wharton and a B.A. from Colby College.
Partner who was previously a Senior Manager in Corporate Development at Pfizer and an analyst at Blackstone and Oppenheimer. Holds an M.B.A. from Columbia and a B.S. from Cornell.
Partner who was previously an investment professional at Paul Capital and a strategy consultant at Health Advances. Holds an M.S. in Biochemistry from Georgetown and a B.A. from Kenyon College.
Principal who was previously in strategy and corporate development at Siemens Healthineers and an investment banking associate at Greenhill. Holds an M.B.A. from Harvard and a B.S. from the University of Virginia.
Chief Accounting Officer who was previously a Senior Manager in EY's asset management assurance practice. Holds an M.S. and B.S. in Accountancy from Wake Forest and is a CPA.
Senior Vice President who previously worked in Global Analytics at AstraZeneca and as a consultant at L.E.K. Holds a PhD from Yale and a B.S. from DePaul University.
Controller who was previously a Manager in PwC's asset and wealth management assurance practice. Holds an M.S. and B.S. in Accounting from the University of Virginia and is a CPA.
CFO who was previously Managing Director and CFO at Siguler Guff & Company and a manager at Ernst & Young. Holds a B.S. in Accounting from Binghamton University and is a CPA.
Leads business development and investor relations, having previously worked at Gladius Capital Management, Utah Retirement Systems, and BlackRock. Holds a B.S. in Physics from Brigham Young University.
Senior Associate who was previously a business development associate at Rejuveron Life Sciences and a consultant at ClearView. Holds a PhD in Genetics from Yale and a B.S. from the University of Virginia.
Vice President who was previously a project leader at Boston Consulting Group. Holds a PhD from the University of Cambridge and degrees in biochemistry from Ghent University.
Director of Operations who previously led private equity marketing at KPMG and began her career in KPMG's audit practice. Holds a B.S. in Accountancy from Villanova University.
Deputy CCO and Associate General Counsel who was previously a compliance officer at Goldman Sachs and a litigation associate at Paul, Weiss. Holds a J.D. from George Washington and a B.A. from SUNY Albany.
General Counsel and CCO who was previously a Partner in the life sciences practices at Covington & Burling and Morrison & Foerster. Holds a J.D. from Harvard Law and an A.B. from Columbia College.
Senior Vice President who was previously a consultant at ClearView Healthcare Partners and completed a PhD at Yale. Holds a B.A. from Amherst College.
Senior Associate who previously spent 13 years at CU Innovations in strategy, business development and licensing, and earlier at Baylor College of Medicine. Holds an M.B.A. from UT Austin and degrees from Baylor University.
Senior Administrative Coordinator who was previously Operations Manager for The Actors Green Room. Holds a B.A. in Music Performance from Winthrop University.
Investments · 1 tracked
founders shown can be your intro pathFund performance · per public LP disclosures · 3
as of Dec 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Oberland Capital Healthcare III LP | — | — | 2.9% | 1.11x | 0.19x |
| Oberland Capital Healthcare Solutions Co-Invest LP | — | — | 23.5% | 1.35x | 0.56x |
| Oberland Capital Healthcare Solutions LP | — | — | 10.6% | 1.22x | 0.58x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Frequently asked questions
- What stage does Oberland Capital invest at?
- Oberland Capital invests at the Growth, Late Stage stages.
- What is Oberland Capital's typical check size?
- Oberland Capital typically writes checks of $50M – $300M.
- What sectors does Oberland Capital focus on?
- Oberland Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Oberland Capital located?
- Oberland Capital is headquartered in New York, US.
Similar investors
Amadeus Capital Partners is a technology investor. It held a first close of $75M on its Amadeus IV Digital Prosperity Fund, focused on late-stage venture and growth companies building online and mobile services for emerging-market middle classes.
B Capital Group is a multistage venture capital firm that invests from seed to late stage, offering value-added support to founders in partnership with management consulting firm BCG.
Capricorn Venture Partners is a Belgium-based venture capital firm managing several funds across health, cleantech, digital, and fusion sectors, accepting pitches from companies raising capital.
DCVC (Data Collective) is a deep tech venture capital firm backing entrepreneurs using computational approaches to solve large real-world problems across many industries. It operates six flagship funds plus DCVC Bio, spanning 13 funds to date.
GV, originally launched as Google Ventures in 2009, is an independent venture capital firm with Alphabet as its sole limited partner. It invests from seed to growth stages across technology and life sciences and supports founders with operating partners and access to Google and Alphabet resources.